Women diagnosed with advanced triple-negative breast cancer who cannot receive immunotherapy now have a new first-line ...

Targeted compound daraxonrasib successfully blocks multiple KRAS variants to double survival limits in clinical trials.

Patients with locally advanced cervical cancer who receive dual checkpoint blockade before standard chemoradiation have high 3-year survival, but outcomes are poorer for those with ‘cold’ tumors.

Patients with previously treated metastatic pancreatic cancer lived roughly twice as long when given an oral pill called ...

AURORA targets a high-unmet-need population: metastatic non-squamous NSCLC with progression on pembrolizumab and platinum ...

BARCELONA, Spain — Long-awaited overall survival data from the KEYNOTE-522 trial has lifted spirits in the triple-negative breast cancer (TNBC) community. The trial confirmed the survival benefit of ...

Rybrevant plus Lazcluze, compared with Tagrisso, showed a trend towards favorable overall survival in EGFR-positive advanced non-small cell lung cancer. In the first line of treatment, Rybrevant ...

Novartis’ Kisqali is getting a leg up in the CDK4/6 breast cancer realm as another rival failed to significantly extend patients’ lives in a pivotal trial. A phase 3 study testing Eli Lilly’s Verzenio ...

What doctors described as a “messy” treatment landscape in early-stage non-small cell lung cancer (NSCLC) could get clearer thanks to a first-in-class overall survival win from Merck & Co.’s Keytruda.

Summit said Harmoni-6 is the first Phase 3 study to show a "statistically significant" survival advantage over a PD-1 inhibitor plus chemotherapy.

Liver is the most common site for distant metastasis in ovarian cancer, with a median overall survival of 11 months for affected patients. A new nomogram was developed using SEER data, identifying age ...